The aim of this study was to evaluate discontinuation and hospitalization rates in patients with schizophrenia spectrum disorder who were treated with long-acting injectable (LAI) antipsychotics. We recorded clinical data about the period before the LAI treatment, when LAI treatment was initiated, and during the LAI treatment. Variables related to early (<8 weeks) and other LAI discontinuations and hospitalization were analyzed. Out of 452 patients, 14.4% of them discontinued their LAI treatment before 8 weeks, another 24.8% of the patients stopped their LAI by themselves later. Early discontinuers were younger, had shorter duration of illness, and less educated. Sixty-two (27.2%) of the patients were hospitalized under LAI treatment and 40...
Non-adherence remains a significant problem in schizophrenia treatment. Discontinuation of treatment...
AbstractThe use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restrict...
Aim & Background: Non-adherence to antipsychotic treatment is a major issue in the management of...
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor adherence ...
Background: Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) t...
PurposeThis study aims to describe factors associated to treatment continuity and psychiatric relaps...
PurposeThis study aims to describe factors associated to treatment continuity and psychiatric relaps...
Purpose: To describe (1) the clinical profiles and the patterns of use of long-acting injectable (LA...
In recent years, measurement of the effectiveness of antipsychotic therapy in schizophrenia has rece...
Background Many patients with schizophrenia discontinue antipsychotic medication, frequently with ad...
Abstract Aim We conducted a chart review to investigate the detailed outcomes of patients with schiz...
Gabriel Kaplan,1,2 Julio Casoy,3 Jacqueline Zummo3 1Behavioral Health Services, Bergen Regional Medi...
Background: Schizophrenia is a severe psychiatric disorder with periods of remission and relapse. As...
Non-adherence remains a significant problem in schizophrenia treatment. Discontinuation of treatment...
AbstractThe use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restrict...
Aim & Background: Non-adherence to antipsychotic treatment is a major issue in the management of...
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor adherence ...
Background: Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) t...
PurposeThis study aims to describe factors associated to treatment continuity and psychiatric relaps...
PurposeThis study aims to describe factors associated to treatment continuity and psychiatric relaps...
Purpose: To describe (1) the clinical profiles and the patterns of use of long-acting injectable (LA...
In recent years, measurement of the effectiveness of antipsychotic therapy in schizophrenia has rece...
Background Many patients with schizophrenia discontinue antipsychotic medication, frequently with ad...
Abstract Aim We conducted a chart review to investigate the detailed outcomes of patients with schiz...
Gabriel Kaplan,1,2 Julio Casoy,3 Jacqueline Zummo3 1Behavioral Health Services, Bergen Regional Medi...
Background: Schizophrenia is a severe psychiatric disorder with periods of remission and relapse. As...
Non-adherence remains a significant problem in schizophrenia treatment. Discontinuation of treatment...
AbstractThe use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restrict...
Aim & Background: Non-adherence to antipsychotic treatment is a major issue in the management of...